
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is a biopharmaceutical company focusing on innovative treatments for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies, and its lead product candidate, lanifibranor, has shown promising results in improving fibrosis and metabolic markers. The positive outlook is bolstered by lanifibranor's unique ability to achieve both MASH resolution and significant fibrosis improvement in clinical trials, with a notable 42% improvement compared to placebo, which could establish it as a best-in-class option in its therapeutic category. Additionally, the potential for lanifibranor to complement existing therapies, particularly GLP-1s, may enhance market adoption and support revenue growth through strategic partnerships, reinforcing Inventiva's financial position in the competitive biopharmaceutical landscape.
Bears say
Inventiva SA faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from its financial losses and clinical development risks. The company reported a net loss of €175.9 million, or €1.62 per share, indicating ongoing financial strain that may limit future operational capabilities. Additionally, potential efficacy or safety issues with its lead product candidate, lanifibranor, in Phase III development, as well as the risk of clinical trial failures and delays in regulatory timelines, further exacerbate concerns regarding the company’s future growth and valuation.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares